Filter By:

Reset
Renal Research

Research activity in the Renal Research program at PHRI includes treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury, and various forms of chronic kidney diseases.

Michael Walsh

Scientist

Michael Walsh
Scientist

Michael Walsh is a Principal Investigator in the Renal research program at PHRI, and an Assistant Professor, Department of Medicine (nephrology), McMaster University. His research activities are in the areas of the treatment of patients who require dialysis, severe glomerular disease, and perioperative acute kidney injury. He has published more than 70 papers and two book chapters.

He holds a Kidney Research Scientist Core Education and National Training (KRESCENT) Program New Investigator award through CIHR and the Kidney Foundation of Canada.  He’s received multiple Top Abstract awards from the Canadian Society of Nephrology, the Chalmers Prize from the Society for Clinical Trials, and the Detweiller Traveling Scholar Award from the College of Physicians and Surgeons of Canada.

Matthew Lanktree

Scientist

Matthew Lanktree
Scientist

Matthew Lanktree is a clinical scientist in adult nephrology genetics who cares for patients with chronic and end-stage kidney disease at St. Joseph’s Healthcare Hamilton and Hamilton Health Sciences. He is an Assistant Professor, Department of Medicine (division of nephrology) and Department of Health Research, Methods, Evidence and Impact, at McMaster University. His research areas of interest are: nephrology genetics; cardiovascular disease in patients with chronic kidney disease; dialysis; and polycystic kidney disease.

He obtained a combined MD and PhD at Western University with research in human genetics before residency in internal medicine and nephrology at McMaster University. He then completed a post-doctoral research fellowship in heritable kidney disease at the University of Toronto before returning to McMaster as faculty in 2019. He has published more than 60 articles in high-impact journals in genetics and medicine, and has set his goal to translate genetic studies into improved care of patients with kidney disease.

Pavel Roshanov

Investigator

Pavel Roshanov
Investigator

Pavel Roshanov, an internal medicine physician and nephrologist, is completing a fellowship in kidney transplantation at McMaster University. He has published more than 50 papers in the areas of perioperative care and medical informatics.

Amit Garg

Associate Scientist

Amit Garg
Associate Scientist

Amit Garg is the Associate Dean, Clinical Research, at the Schulich School of Medicine & Dentistry, Western University, has practiced as a staff nephrologist at the London Health Sciences Centre in London, Ontario, Canada since 2003, and is a Professor of Medicine, Epidemiology and Biostatistics at Western University, with a cross-appointment in the Department of Health Research Methods, Evidence, and Impact (HEI) at McMaster University. A past president of the Canadian Society of Nephrology, Amit Garg serves as the current Ontario Lead of the Kidney, Dialysis and Transplantation Program at ICES.

He values his ongoing collaborations with PJ Devereaux and other leading clinician-scientists at PHRI, which has led to several sub-studies funded by the Canadian Institutes of Health Research which examined the effects of perioperative interventions on the risk of acute kidney injury (off-pump cardiopulmonary bypass surgery) in the CORONARY study, and more. A current interest is in pragmatic randomized trials embedded into routine healthcare delivery.

 

Amber Molnar

Associate Scientist

Amber Molnar
Associate Scientist

Amber Molnar is a nephrologist at St. Joseph’s Healthcare in Hamilton, and Assistant Professor, Department of Medicine, Division of Nephrology, McMaster University. Her research program focuses on improving the pre-dialysis care of patients with advanced chronic kidney disease (CKD) and reducing cardiovascular complications in patients with CKD.

She holds a Kidney Research Scientist Core Education and National Training (KRESCENT) program’s New Investigator Award through CIHR and the Kidney Foundation of Canada. Amber earned her M.D. at the University of Saskatchewan followed by internal medicine training at Western University, and completed her nephrology and MSc (Epidemiology) training at the University of Ottawa.

David Collister

Associate Investigator

David Collister
Associate Investigator

David Collister is a nephrologist at the University of Alberta Hospital and Assistant Professor in the Department of Medicine, Division of Nephrology, at the University of Alberta. He completed a PhD in Health Research Methodology at McMaster University and research fellowship at the Population Health Research Institute (PHRI) focused on run-in periods and patient oriented research in kidney disease including the DISCO-RLS trial.

His research program focuses on symptom management in patients with kidney disease and, in particular, randomized controlled trials of therapies to alleviate symptoms in chronic kidney disease and dialysis. He currently holds a Kidney Research Scientist Core Education and National Training (KRESCENT) New Investigator Award. His research program is funded by the Canadian Institutes of Health Research and the Kidney Foundation of Canada. He is the principal investigator of RESET-DIALYSIS, a prospective cohort study of patients with advanced chronic kidney disease initiating dialysis which will examine the responsiveness of uremic symptoms to dialysis and uremic symptom pathophysiology with metabolomics, proteomics and genomics. He is the principal investigator of DISCO-POT, a randomized controlled trial of nabilone versus placebo for the treatment of uremic pruritus in adults with kidney failure treated with dialysis. He is also interested in the intersection between transgender, non-binary and gender diverse populations and kidney disease.

Lonnie Pyne

Research Fellow

Lonnie Pyne
Research Fellow

Lonnie Pyne is a Research Fellow at PHRI, supervised by Dr. Michael Walsh, and a MSc student in the Health Research Methodology program at McMaster. Lonnie is a Clinical Scholar in the Department of Medicine, Division of Nephrology at McMaster University. Lonnie obtained his medical degree from Western University. He completed his internal medicine residency and nephrology fellowship at McMaster University.

His current research interests include chronic kidney disease, surrogate outcomes in nephrology, cardiovascular outcomes in kidney disease, and vasculitis.

Jessica Tyrwhitt

Program Manager

Jessica Tyrwhitt
Program Manager

Jessica Tyrwhitt has more than 10 years’ experience in coordinating and managing large, international clinical trials. She oversees interventional trials, registries, and observational research studies looking at primary and secondary prevention of cardiovascular disease in a variety of therapeutic areas, including cardiology, thrombosis, nephrology, cardio-oncology and diabetes.

She holds an Honours Bachelor of Science Degree & Business from the University of Waterloo.

 

Courtney Christou

Project Manager

Courtney Christou
Project Manager

Courtney has more than eight years of experience working in both industry and academic research. She primarily manages large international drug trials that focus primarily on prevention of cardiovascular disease (TIPS-3, COMPASS and ORIGIN trials) and chronic kidney disease (ACHIEVE, RECORD and DISCO-RLS trials).

She holds an Honours Bachelor of Applied Sciences with a Major in Kinesiology and a Diploma in Fitness and Health Promotion from the University of Guelph-Humber.

ongoing

ACHIEVE

Renal

Globally more than two million people receive dialysis for end-stage renal disease (ESRD) and 650,000...

ongoing

DISCO-RLS

Renal

Restless legs syndrome (RLS) affects 30% of dialysis patients, and is associated with a decreased...

ongoing

RECORD

Renal

RECORD stems from Canadians Seeking Solutions and Innovations for Chronic Kidney Disease (Can SOLVE CKD)....

completed

Risk Factors for Suboptimal Dialysis Initiation

Renal

At the end of 2014, 20,690 Canadians were receiving chronic dialysis. Unfortunately, many of these...

completed

PHASE

Renal

Mineralocorticoid receptor antagonism reduces morbidity and mortality in patients with heart failure, but the safety...

completed

TARGET

Renal

The TARGET trial investigated intensive versus liberalized phosphate control in hemodialysis recipients. The objective of...

Back To Top